A Phase 2a, randomized, double-blind, placebo-controlled study of oral FXR modulator EYP001a combined with nucleos(t)ide analogues (NA) in virologically suppressed chronic hepatitis B patients to improve functional cure rates

Project: Research

Project Details

StatusActive
Effective start/end date20/12/19 → 19/12/24

Keywords

  • clinical trial
  • treatment safety
  • Hepatitis B
  • phase 2 study
  • treatment effiacy